A Baltimore biotechnology company has raised $4 million, to help bring its therapeutic treatment targeting rare genetic diseases closer to market. Elixirgen Therapeutics Inc. filed documents with the U.S. Securities and exchange commission detailing its recent Series A round. The round included one undisclosed investor. CEO Akihiro Ko said the funding will go toward continued development and clinical trials for Elixirgen’s first drug candidate. Elixirgen’s key technology is based on a special…
from https://www.bizjournals.com/baltimore/news/2018/07/09/baltimore-based-biotech-dedicated-to-developing.html?ana=RSS&s=article_search
via http://baltimorecheckbook.tumblr.com/post/175709329402
No comments:
Post a Comment